A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor

Pancreatic Ductal Adenocarcinoma (PDAC) is a disease with a great heterogeneity in the response to treatments. To improve the responsiveness to treatments there are two different approaches, the first one consist to develop new and more efficient drugs that intent to cure all patients and the second...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Gayet, Odile, Loncle, Celine, Duconseil, Pauline, Gilabert, Marine, Lopez, Maria Belen, Moutardier, Vincent, Turrini, Olivier, Calvo, Ezequiel, Ewald, Jacques, Giovannini, Marc, Gasmi, Mohamed, Bories, Erwan, Barthet, Marc, Ouaissi, Mehdi, Goncalves, Anthony, Poizat, Flora, Raoul, Jean Luc, Secq, Veronique, Garcia, Stephane, Viens, Patrice, Dusetti, Nelson, Iovanna, Juan
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2014
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359252/
https://ncbi.nlm.nih.gov/pubmed/25481873
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы